Maze Therapeutics, INC Form 4 insider transactions

Maze Therapeutics' Chief Scientific Business Officer, Atul Dandekar, executed a pre-planned sale of common stock following the exercise of options.

Maze Therapeutics, Inc. director Neil Kumar was granted 33,417 stock options with an exercise price of $30.38, vesting monthly over three years.

Maze Therapeutics' President of R&D & CMO, Harold Bernstein, exercised options and sold a significant number of common shares under a 10b5-1 plan.

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, exercised 30,000 stock options and subsequently sold all acquired shares under a pre-arranged trading plan.

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, exercised options and sold 15,000 shares of common stock under a Rule 10b5-1 plan.

Amy Bachrodt, SVP of Finance at Maze Therapeutics, executed option exercises and subsequent sales of common stock totaling 5,000 shares under a pre-arranged 10b5-1 trading plan.

Maze Therapeutics' CSBO Atul Dandekar reported exercising stock options and selling 7,500 shares of common stock under a pre-arranged 10b5-1 trading plan.

Amy Bachrodt, SVP of Finance at Maze Therapeutics, executed a pre-planned sale of 5,000 common shares after exercising stock options on January 22, 2026.

Maze Therapeutics' President of R&D & CMO, Harold Bernstein, exercised stock options and sold 25,156 shares of common stock for a significant profit.

Catherine A. Sohn, a director at Maze Therapeutics, Inc., executed pre-planned sales of common stock totaling 29,413 shares following option exercises.

Maze Therapeutics' President of R&D & CMO, Harold Bernstein, exercised stock options and subsequently sold shares totaling 4,844 units in early January 2026, pursuant to a pre-arranged 10b5-1 trading plan.

Amy Bachrodt, SVP of Finance at Maze Therapeutics, executed pre-planned option exercises and subsequent sales of common stock, realizing significant gains.

Maze Therapeutics' Chief Strategy and Business Officer, Atul Dandekar, exercised stock options and subsequently sold a significant portion of common stock under a pre-arranged 10b5-1 trading plan.

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, exercised options and sold 45,000 shares for approximately $1.8 million under a pre-arranged trading plan.

Amy Bachrodt, SVP of Finance at Maze Therapeutics, exercised stock options and subsequently sold an equal number of shares totaling 15,000, as part of a pre-arranged 10b5-1 trading plan.

Maze Therapeutics Director Charles J. Homcy received 1,489 shares of common stock through a pro rata distribution from Third Rock Ventures affiliates.

Third Rock Ventures IV, L.P. distributed 1.6 million shares of Maze Therapeutics common stock to its partners for no consideration.

Maze Therapeutics Director Charles J. Homcy reported gifting 28,423 shares of common stock, reducing his direct beneficial ownership.

Herve Hoppenot, a Director at Maze Therapeutics, Inc., was granted 36,000 stock options with an exercise price of $27.52.

Maze Therapeutics, Inc. granted 22,000 restricted stock units to its General Counsel and Corporate Secretary, Courtney Phillips, vesting over two years.

Maze Therapeutics, Inc. has granted its Chief Scientific Business Officer, Atul Dandekar, 25,000 restricted stock units, aligning executive incentives with shareholder value.

Maze Therapeutics CEO Jason V Coloma was granted 100,000 Restricted Stock Units, vesting over two years, as disclosed in a recent SEC Form 4 filing.

Maze Therapeutics, Inc. granted 40,000 Restricted Stock Units to Harold Bernstein, President, R&D & CMO, as part of his compensation, vesting over two years.

Amy Bachrodt, SVP of Finance at Maze Therapeutics, Inc., was granted 22,000 Restricted Stock Units, vesting over two years.

Maze Therapeutics Director Daniel K. Spiegelman received a grant of 18,000 stock options with an exercise price of $23.67, vesting monthly over nine months.

Catherine A. Sohn, a Director at Maze Therapeutics, acquired 18,000 stock options with an exercise price of $23.67, vesting monthly starting October 1, 2025.

Maze Therapeutics director Richard H. Scheller was granted 18,000 stock options with an exercise price of $23.67, vesting monthly starting October 1, 2025.

Maze Therapeutics director Jonathan E. Lim was granted 18,000 stock options with an exercise price of $23.67, vesting monthly starting October 1, 2025.

Sekar Kathiresan, a Director at Maze Therapeutics, Inc., was granted 18,000 stock options with an exercise price of $23.67, vesting monthly starting October 1, 2025.

Maze Therapeutics Director Charles J. Homcy was granted 18,000 stock options with an exercise price of $23.67, vesting monthly starting October 1, 2025.